Kyorin Holdings Inc represents values of integrity, innovation, and patient-centric approach. With a dedicated corporate philosophy, the company strives to contribute to improving the quality of life and healthcare services. Kyorin Holdings Inc prioritizes ethical business practices, ensuring transparency and trustworthiness in all its operations. Through continuous research and development, the company aims to deliver cutting-edge pharmaceutical and healthcare solutions. With a focus on patient well-being, Kyorin Holdings Inc fosters collaborations and partnerships to enhance medical advancements and positively impact society.

Kyorin Holdings Inc is primarily present in Japan.

Kyorin Holdings Inc, a renowned company in the stock market, has achieved significant milestones throughout its history. With a strong commitment to excellence, Kyorin Holdings Inc has successfully expanded its portfolio and established a solid presence in various sectors. Notably, the company has achieved remarkable growth in the pharmaceutical industry, introducing innovative drugs and improving healthcare services. By leveraging its expertise and strategic partnerships, Kyorin Holdings Inc has consistently delivered impressive financial results, enhancing shareholder value and solidifying its position as a market leader. Through its continuous efforts in research and development, Kyorin Holdings Inc stands as a testament to its unwavering dedication to progress and success.

Kyorin Holdings Inc is a renowned Japanese pharmaceutical company with a rich history and solid background. Established in 1947, Kyorin Holdings Inc has been at the forefront of medical innovation, delivering high-quality healthcare products and services to customers worldwide. With a focus on research and development, Kyorin Holdings Inc has earned a stellar reputation in the industry for its dedication to advancing medical solutions. Over the years, the company has expanded its portfolio to include a diverse range of therapeutic areas, ranging from respiratory products to antiallergic medications. Kyorin Holdings Inc continues to strive for excellence in the healthcare sector, driven by its commitment to improving the well-being and quality of life for patients globally.

Kyorin Holdings Inc faces competition from various companies in the market. Some of the main competitors of Kyorin Holdings Inc include Takeda Pharmaceutical Company Limited, Astellas Pharma Inc, and Daiichi Sankyo Company, Limited. These companies operate in the same industry and offer similar products and services. However, Kyorin Holdings Inc has its unique strengths and is known for its innovative approach, superior quality, and strong customer base. With its strong presence and strategic initiatives, Kyorin Holdings Inc continues to thrive in the competitive market, ensuring sustainable growth and delivering value to its stakeholders.

Kyorin Holdings Inc is primarily active in the pharmaceutical and healthcare industries.

Kyorin Holdings Inc, a leading pharmaceutical company based in Japan, primarily focuses on the research, development, manufacturing, and sales of pharmaceutical products. Their business model entails a comprehensive approach that spans across the entire pharmaceutical value chain. Kyorin Holdings Inc leverages its expertise to deliver innovative and high-quality drugs, targeting various medical areas such as respiratory diseases, allergies, infectious diseases, and more. By combining advanced research and development capabilities with a strong sales and marketing network, Kyorin Holdings Inc strives to enhance people's health and well-being through the provision of effective and safe pharmaceutical solutions.

مُعامل القيمة السوقية إلى الأرباح لـ Kyorin Pharmaceutical Co هو ١٨٫١٥.

مُعامِل القيمة إلى المبيعات Kyorin Pharmaceutical Co هو ٠٫٨١.

نقاط جودة AlleAktien لـ Kyorin Pharmaceutical Co هي 4/10.

Kyorin Pharmaceutical Co الإيرادات هي ١١٩٫٥٣ مليارات JPY.

صافي الربح Kyorin Pharmaceutical Co هو ٥٫٣٢ مليارات JPY.

Kyorin Holdings Inc. is a Japanese company that operates in various business sectors. The company was founded in 1950 and is headquartered in Tokyo, Japan. Kyorin Holdings Inc. is listed on the Tokyo Stock Exchange and also operates internationally. The company operates in three main business areas: pharmaceuticals, life science, and investment. In the pharmaceutical business sector, the company develops and distributes a wide range of prescription and over-the-counter drugs. Kyorin Holdings Inc. has its own production facility in Kashima, Japan, where these products are manufactured. The company focuses on cardiovascular, respiratory, urology, dermatology, and allergy areas. Some of the well-known products include the respiratory medication Eucrisa and the heart medication Inderal. In the life science sector, Kyorin Holdings Inc. operates a wide range of biotechnology and diagnostic companies. The company invests heavily in research and development to develop innovative products and technologies. Some of the well-known brands include the biotechnology company Kainos Medicine and the diagnostics company Paraxel. Kyorin Holdings Inc. also invests in other companies and operates an investment business sector. The company operates globally and focuses on various industries such as biotechnology, IT, financial services, and real estate. Kyorin Holdings Inc. also has a subsidiary called Kyorin Venture Capital, which specializes in supporting startups and their financing. To understand Kyorin Holdings Inc.'s business model, it is important to understand that the company has a diversified portfolio focusing on three main business areas. The company strives to be a leading provider in each of its sectors and to grow through research and development. Kyorin Holdings Inc. also has a clear growth strategy, focusing on global expansion and tapping into new markets. The company builds partnerships with other pharmaceutical and biotech companies to expand its market-leading position. Conclusion: Kyorin Holdings Inc.'s business model is focused on being a leading provider of pharmaceuticals, biotechnology products, and investment services. The company aims to continuously grow through research and development and expand into new markets through partnerships and strategic investments.

يوزع Kyorin Pharmaceutical Co أرباحًا قدرها ٥٢٫٠٠ JPY من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Kyorin Pharmaceutical Co في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـKyorin Pharmaceutical Co هو JP3247090008.

الرمز المُختصر لـ Kyorin Pharmaceutical Co هو 4569.T.

خلال آخر 12 شهراً، دفعت Kyorin Pharmaceutical Co توزيعات أرباح بقيمة ٥٢٫٠٠ JPY . وهذا يعادل عائد توزيعات أرباح يقارب ٣٫٠٩ %. ومن المتوقع أن تدفع Kyorin Pharmaceutical Co خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ٥٢٫٤٨ JPY.

نسبة توزيعات الأرباح الحالية لـ Kyorin Pharmaceutical Co هي ٣٫٠٩ %.

Kyorin Pharmaceutical Co يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر أكتوبر, أبريل, أكتوبر, أبريل.

Kyorin Pharmaceutical Co دفعت توزيعات الأرباح كل عام خلال الـ22 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة ٥٢٫٤٨ JPY. وهذا يعادل عائد توزيعات أرباح قدره ٣٫١٢ %.

Kyorin Pharmaceutical Co يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ٢٠ JPY من Kyorin Pharmaceutical Co المُعلن عنها في ١‏/١٢‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٧‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١‏/١٢‏/٢٠٢٤.

في العام 2023، وزعت Kyorin Pharmaceutical Co ٥٢ JPY كأرباح أسهم.

يتم توزيع أرباح Kyorin Pharmaceutical Co بالعملة JPY.